Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wood Group wants Sidara takeover finalised before end of June - report

(Sharecast News) - Wood Group is expected to request an extension to the so-called 'put up or shut up' takeover deadline for Sidara in an attempt to get the deal done before the end of June. According to Sky News, which quoted "industry insiders", Wood Group wants to finalise a £242m proposed takeover from Sidara before the end of the month, when a waiver of its debt covenants is scheduled to expire.

The current PUSU deadline is due to expire at 1700 BST on Thursday, having already been extended following the initial proposal from Sidara on 14 April. Under the current deadline, Sidara must either give a firm intention to make an offer or walk away.

The 35p-per-share offer is just a fraction of the 230p price tag proposed by Sidari in May 2024, before revelations about corporate governance and questionable financial results tanked the stock.

In a statement to the market last month, Wood Group said it was continuing to work with Sidara in relation to the pre-conditions to the most recent potential offer.

"In particular, Wood and Sidara are continuing to engage with Wood's lenders and noteholders in relation to both the Debt Modifications and the Sidara Liquidity Arrangements [...], and Wood is continuing to work with its auditor towards the publication of Wood's audited accounts for the financial year ended 31 December 2024."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.